1-甲基-5-硝基-1H-吲哚-2-羧酸乙酯 | 71056-57-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-甲基-5-硝基-1H-吲哚-2-羧酸乙酯
• 英文名称: ethyl 1-methyl-5-nitro-1H-indole-2-carboxylate
• 英文别名: 1-methyl-5-nitro-indole-2-carboxylic acid ethyl ester；ethyl 1-methyl-5-nitro-1H-indole 2-carboxylate；Ethyl 1-methyl-5-nitro-2-indolecarboxylate；Ethyl-1-methyl-5-nitroindol-2-carboxylat；ethyl 1-methyl-5-nitroindole-2-carboxylate
• CAS: 71056-57-0
• 化学式: C₁₂H₁₂N₂O₄
• 分子量: 248.238
• InChiKey: DTGUXIWYZIAUIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  77
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-甲基-5-硝基-1H-吲哚-2-羧酸乙酯 在 Pd/C 四溴化碳 、 氢气 、 三甲基铝 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 苯酚 为溶剂， 20.0~130.0 ℃ 、344.74 kPa 条件下， 反应 10.5h， 生成 6-(4-chlorophenyl)-3-(2-{[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]methyl}-1-methyl-1H-indol-5-yl)thieno[3,2-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-Based Melanin-Concentrating Hormone Receptor 1 Antagonist

  摘要：

  Genetic manipulation studies in mice at both the MCH receptor 1 (MCHR1) as well as the MCH peptide levels have implicated MCHR1 as a key player in energy homeostasis. The phenotype exhibited by these studies, that is, increased metabolic rate, resistance to high fat diet, and subsequent weight loss, has spurred considerable efforts to develop antagonists of MCHR1. In continuation of efforts directed toward this goal, the present work capitalizes on the putative binding mode of an MCH antagonist, resulting in the identification of several novel chemotypes that are potent and selective MCHR1 antagonists. In addition, the favorable pharmacokinetics of representative examples has allowed for the evaluation of an MCHR1 antagonist in a high fat diet-induced obese rodent model of obesity. The tolerability of the right-hand side of the template for diverse chemotypes accompanied by favorable effects on weight loss enhances the attractiveness of this template in the pursuit toward development of effective anti-obesity agents.

  DOI：

  10.1021/jm060814b
• 作为产物：
  描述：

  5-硝基吲哚-2-羧酸乙酯 、 碘甲烷 在 potassium carbonate 作用下， 以 水 、 乙腈 为溶剂， 生成 1-甲基-5-硝基-1H-吲哚-2-羧酸乙酯
  参考文献：
  名称：

  Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals

  摘要：

  本发明涉及公式I的氨基烷基取代芳香双环化合物，这些化合物是有价值的药用活性化合物，例如适用于治疗肥胖症、2型糖尿病、动脉硬化、高血压、感觉异常、抑郁症、焦虑症、焦虑神经症、精神分裂症、与昼夜节律相关的疾病以及药物滥用，同时还能正常化脂质代谢。

  公开号：

  US20030212070A1

文献信息

• Triamide-substituted heterobicyclic compounds
  申请人：Pfizer Inc.

  公开号：US20030187053A1

  公开（公告）日：2003-10-02

  The invention relates to triamide MTP/ApoB inhibitors of the formula 1 1 wherein R 1 -R 8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

  本发明涉及三酰胺MTP/ApoB抑制剂，其化学公式为1，其中R1-R8如说明书所述，以及包含这些化合物的药物组合物及其用途，以及制备这些化合物的方法。本发明的化合物可用于治疗肥胖和脂质紊乱。
• Viral polymerase inhibitors
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20030236251A1

  公开（公告）日：2003-12-25

  An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: 1 wherein R 1 is selected from: H, haloalkyl, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-7 )cycloalkyl, (C 2-6 )alkynyl, (C 5-7 )cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 6-10 )bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR 5 , wherein R 5 is H, halogen, haloalkyl, (C 1-6 )alkyl, (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; X is N or CR 5 ; D is N or CR 5 ; each of Y 1 and Y 2 is independently O or S; Z is O, N, or NR z wherein R z is H, (C 1-6 )alkyl, (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; R 3 and R 4 are each independently H, (C 1-6 )alkyl, first (C 3-7 )cycloalkyl or 6- or 10-membered aryl, Het (C 1-6 )alkyl-6- or 10-membered aryl, (C 1-6 )alkyl-Het; or each R 3 and R 4 are independently covalently bonded together to form second (C 3-7 )cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R 3 or R 4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R 7 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; or R 7 is covalently bonded to either of R 3 or R 4 to form a heterocycle; A is (C 1-6 ) alkyl-CONHR 8 wherein R 8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.

  公式I所代表的化合物的异构体、对映体、非对映异构体或互变异构体，其中R1选自：H、卤代烷基、(C1-6)烷基、(C2-6)烯基、(C3-7)环烷基、(C2-6)炔基、(C5-7)环烯基、6或10元芳基、Het均可选择性地取代；R2选自(C1-6)烷基、(C3-7)环烷基、(C6-10)双环烷基、6-或10元芳基、或Het均可选择性地取代；B为N或CR5，其中R5为H、卤素、卤代烷基、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；X为N或CR5；D为N或CR5；Y1和Y2中的每一个独立地为O或S；Z为O、N或NRz，其中Rz为H、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；R3和R4各自独立地为H、(C1-6)烷基、第一(C3-7)环烷基或6-或10元芳基、Het(C1-6)烷基-6-或10元芳基、(C1-6)烷基-Het；或每个R3和R4独立地共价结合在一起形成第二(C3-7)环烷基，或杂环，均可选择性地取代；或当Z为N时，R3或R4中的任一者独立地与之共价结合形成含氮杂环；R7为H、(C1-6烷基)、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；或R7与R3或R4中的任一者共价结合形成杂环；A为(C1-6)烷基-CONHR8，其中R8为6-或10元芳基，或Het；或A为6-或10元芳基，或Het所述芳基或Het可选择性地取代；或其盐或衍生物；这类化合物是HCV NS5B聚合酶的有效抑制剂。
• Synthesis, Biological Evaluation, and Structure−Activity Relationships of 3-Acylindole-2-carboxylic Acids as Inhibitors of the Cytosolic Phospholipase A₂
  作者：Matthias Lehr

  DOI：10.1021/jm960863w

  日期：1997.8.1

  Replacement of the carboxylic acid group in position 2 of the indole with an acetic or propionic acid substituent led to a decrease of inhibitory potency. Enzyme inhibition was optimal when the acyl residue in position 3 had a length of 12 or more carbons. Conformational restriction of the acyl residue did not influence activity. Introduction of alkyl chains at position 1 of the indole with 8 or more carbons

  制备3-酰基吲哚-2-羧酸衍生物，并评价其抑制完整牛血小板的胞质磷脂酶A2的能力。为了定义酶抑制的结构要求，对羧酸基，酰基残基和位置1的部分进行了系统修饰。此外，将不同的取代基引入到吲哚的苯基部分中。用乙酸或丙酸取代基取代吲哚的2位上的羧酸基导致抑制效力的降低。当位置3上的酰基残基具有12个或更多碳原子时，酶抑制作用最佳。酰基残基的构象限制不影响活性。在具有8个或更多个碳的吲哚的位置1处引入烷基链导致活性降低。然而，发现用羧酸部分取代此类化合物的ω-甲基会显着增加抑制效力。在测试的吲哚衍生物中，1- [2-（4-羧基苯氧基）乙基] -3-十二烷酰基吲哚-2-羧基酸（29b）具有最高的效价。IC50为0.5 microM，它的活性比标准cPLA2抑制剂花生四烯酸三氟甲基酮（IC50：11 microM）高约20倍。
• Phosphate mimics and methods of treatment using phosphatease inhibitors
  申请人：Sugen, Inc.

  公开号：US20040138255A1

  公开（公告）日：2004-07-15

  The invention relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are related to cellular signal transduction, in particular, protein tyrosine phosphatase, and therefore are expected to be useful in the prevention and treatment of disorders associated with abnormal protein tyrosine enzyme related cellular signal transduction such as cancer, diabetes, immuno-modulation, neurologic degenerative diseases, osteoporosis and infectious diseases. The invention also relates to the use of compounds containing fluoromethyl sulfonyl groups as phosphate mimics. These mimics may be used to inhibit, regulate or modulate the activity of a phosphate binding protein in a cell.

  本发明涉及三氟甲基磺酰和三氟甲基磺酰胺化合物及其生理上可接受的盐和前药。这些化合物预计能够调节与细胞信号转导相关的蛋白酪氨酸酶的活性，特别是蛋白酪氨酸磷酸酶，因此预计在预防和治疗与异常蛋白酪氨酸酶相关的细胞信号转导障碍，如癌症、糖尿病、免疫调节、神经退行性疾病、骨质疏松症和传染病方面有用。本发明还涉及含有氟甲基磺酰基团的化合物作为磷酸酯模拟物的用途。这些模拟物可用于抑制、调节或调节细胞中的磷酸结合蛋白的活性。
• 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD.

  公开号：US20150210640A1

  公开（公告）日：2015-07-30

  A compound represented by formula (1) (in the formula: ring-D represents a three- to eight-membered hydrocarbon ring; R a represents an optionally substituted amino C 1-6 alkyl group or the like; R b1 and R b2 each independently represent a hydrogen atom, a halogen atom, or the like; R c represents an optionally substituted C 6-10 aryl group or the like; R d represents a hydrogen atom or the like; and ring-Q represents a (hetero)aryl group or the like which may be substituted with a carboxyl group or the like) or a pharmaceutically acceptable salt thereof exhibits an excellent FXIa inhibitory activity, and is useful as a therapeutic agent against thrombosis or the like.

  化合物的化学式为（1）（其中，环D代表3-8个碳原子的碳氢环；R代表可选择性取代的氨基C1-6烷基或类似物；Rb1和Rb2各自独立地代表氢原子、卤素原子或类似物；Rc代表可选择性取代的C6-10芳基或类似物；Rd代表氢原子或类似物；环Q代表（杂）芳基或类似物，可被羧基或类似物取代），或其药学上可接受的盐，具有出色的FXIa抑制活性，可用作治疗血栓或类似疾病的治疗剂。